Ratings OmniAb, Inc.

Equities

OABI

US68218J1034

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
4.35 ^USD	-2.90%		-0.91%	-29.50%

May. 29	Omniab Insider Bought Shares Worth $1,059,840, According to a Recent SEC Filing	MT
May. 09	Earnings Flash (OABI) OMNIAB Reports Q1 Revenue $3.8M, vs. Street Est of $5.9M	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
OMNIAB, INC.	-29.50%	510M	-
MODERNA, INC.	+43.36%	54.63B	B-
IQVIA HOLDINGS INC.	-5.31%	39.92B	B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B	B-
CELLTRION, INC.	-12.56%	26.22B	C
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B	B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B	B+
BIO-TECHNE CORPORATION	+0.04%	12.16B	B+
MEDPACE HOLDINGS, INC.	+26.04%	11.94B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes